Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Smart Insulin Pens Market Outlook (2023 to 2033)

The smart insulin pens market is estimated to be valued at US$ 3,927.3 million in 2023 and is expected to be valued at US$ 8,750.7 million by 2033. The adoption of smart insulin pens is likely to advance at a CAGR of 8.3% during the forecast period.

Smart insulin pulps are increasingly coming in the limelight. As the world reels under the ever growing diabetic population burden, healthcare stakeholders and patients alike are investigating novel therapeutic approaches. Hence, smart insulin pumps are likely to emerge as a good fit. Ever increasing hospital workflows is prompting investments in cloud-based insulin level monitoring approaches, thus widening expansion prospects.

Manufacturers are especially emphasizing on increasing Bluetooth connected smart insulin pens availability, given its ease of configuration with multiple virtual interfaces, including both Android and Apple operating systems. Also, treatment for type-2 diabetes is expected to witness a significant incline, thus generating demand in the segment.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for smart insulin pens. The report tracks the global sales of smart insulin pens in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on the healthcare industry in general, and smart insulin pens in particular.

Attribute Details
Estimated Market Size (2023) US$ 3,927.3 million
Projected Market Size (2033) US$ 8,750.7 million
CAGR through (2023 to 2033) 8.3%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Global Smart Insulin Pens Market Outlook Compared To 2023 to 2033 Forecast

According to Future Market Insights, the smart insulin pens market is witnessing impressive growth every year, as more patients are opting for therapies which are either minimally invasive or non-invasive in nature. Growing workflow complications arising due to the ever swelling diabetic patient pool is prompting healthcare organizations to streamline operations, thus inclining demand.

Throughout 2022 and beyond, growth prospects are expected to remain bright, with revenue share highly likely to surpass US$ 1000 million in the short run. In the long-run, the smart insulin pens market is expected to post massive gains, expanding at an 8.3% CAGR through 2033.

Period Market Size (in US$ million)
2017 US$ 2,661.3 million
2022 US$ 3,627.0 million
2023 US$ 3,927.3 million
2033 US$ 8,750.7 million

Empowering Lives through Innovative Solutions: Unleashing the Growth Potential of Advanced Diabetes Management Technologies

The global burden of diabetes is increasing with each passing year. As per the International Diabetes Federation, global diabetes prevalence in 2019 was estimated to be 9.3% or 463 million people. This number is poised to increase to 578 million, or 10.2% of the global population by 2030, and eventually to 700 million (10.9%) by 2045 respectively. The prevalence is higher in urban areas (10.8%) than rural areas (7.2%).

These alarming increase rates are majorly attributed to growing cases of obesity which is a direct outcome of sedentary lifestyle patterns. Inadequate physical activity has rendered individuals highly susceptible to such chronic ailments, thus necessitating the establishment of a robust healthcare infrastructure. As diabetic patients require constant insulin levels monitoring, the scope for smart insulin pins is widening with each passing day.

Managing diabetic patients’ workflow is often a time consuming and tedious process, as it involves copious amounts of data collection, processing and assimilation, besides ensuring that insulin dosage is administered on a timely basis. Hence, recent years have witnessed an explosion of smart insulin pen manufacturers who offer highly specialized solutions to streamline diabetic patient management. For instance, Insulet Corporation’s Omnipod DASH® Insulin Management System provides up to 3 days of non-stop insulin management without the need for multiple daily injections.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Silencing the Scalpel: The Rise of Painless Surgery and its Expanding Horizons

World over, the demand for non-invasive or minimally invasive surgeries is experiencing a sharp incline, with documented instances of patient trauma and injuries inducing further complications. Also, invasive surgical procedures are known to increase the risk of infections as the exposed wound may attract potential microbes which lead to further deterioration of patient health.

Conventional insulin delivery is mostly done subcutaneously and if the insulin is injected deeper into the muscle, the body absorbs it too quickly. This approach is quite painful for patients. Hence, medical practitioners are relying on smart insulin jet injectors, which permit insulin injection without the use of a needle. Insulin jet injectors typically consist of three parts- the delivery device, a disposable injector nozzle and a disposable insulin vial adapter.

Jet injectors are known to include faster delivery of insulin to the bloodstream. An insulin jet injector allows the insulin to spread over a larger area in the lower layer of the skin compared to a needle. As a result, the insulin moves into your bloodstream faster than it would from a needle injection. At present, this technology is still in its foundational stages, with only two manufacturers- Spirit Healthcare (InsuJetTM) and Injex- operating in the market. However, future prospects are expected to be highly promising.

Unleashing the Power of Convenience: Exploring the Abundance of Opportunities in Homecare Insulin Delivery

With the bulk of the global diabetes incidence concentrated amongst the geriatric population pool, smart insulin pens for homecare insulin delivery is anticipated to acquire massive traction in forthcoming years. The use of insulin pens at home helps reduce hospital visits, thus saving patients a lot of time and finances. The highly portable nature of smart insulin pens renders it the primary choice for home grade insulin administration.

Homecare diabetes treatment, while in prominence since a long time, has especially acquired importance in the wake of the corona virus pandemic crisis. The highly contagious and fatal nature of these diseases has compelled patients to reduce the number of hospital visits, compelling them to opt for home grade treatment. With a few countries experiencing a second wave, home grade insulin delivery is become all the more important.

The simplistic nature of smart insulin pens, with regards to ease of access to key applications monitoring dosage administration and food intake, their relatively simple user interface and ease of availability are also largely expected to widen future growth opportunities.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Navigating the Hurdles: Overcoming Key Challenges in the Smart Insulin Pens Market Growth

High costs associated with smart insulin pens and other diabetes treatment approaches poses a significant detriment to their adoption, particularly across low and middle income countries. These regions have a relatively inferior healthcare infrastructure as they may lack the adequate resources to support robust research and development activities. Fortunately, government campaigns are helping alleviate this shortcoming.

These products are subject to intense scrutiny by appropriate regulatory authorities, amid the fact that these are potential life-saving approaches. As a result, governments want to ensure that the product which is available in the market is absolutely beyond suspicion or doubt. This is often a very lengthy procedure, often taking a lot of time, which delays the availability of new therapeutic approaches.

Comparative View of the Adjacent Markets

Smart Insulin Pens Market:

Attributes Smart Insulin Pens Market
CAGR (2023 to 2033) 8.3%.
Market Value (2033) US$ 8,750.7 million
Opportunity Revolutionary AI-powered insulin dose optimization for personalized diabetes management.
Key Trends Next-generation connectivity and enhanced data analytics transforming smart insulin pens.

Insulin Pens Market:

Attributes Insulin Pens Market
CAGR (2023 to 2033) 6.5%
Market Value (2033) US$ 66 billion
Opportunity Growing intake of unhealthy or processed food.
Key Trends Advancement in the creation of automated intelligent insulin pens.

Insulin Patch Pumps Market:

Attributes Insulin Patch Pumps Market
CAGR (2023 to 2033) 11%
Market Value (2033) US$ 2.7 billion
Opportunity AI integration driving efficiency boost in insulin patch pumps implementation.
Key Trends Growing adoption of reusable insulin patch pumps.

Country-wise Insights

The Land of Opportunity: Unveiling the Lucrative Horizon of the United States Smart Insulin Pens Market

The Centers for Disease Control and Prevention (CDC) estimates that over 34 million Americans suffer from diabetes, representing over a tenth of the population as of 2020. Moreover, as per the American Diabetes Association (ADA), there are over a million new cases of diabetes across the country annually. An estimated 88 million adults have prediabetes, accounting for 34.5% of the American adult population.

Factoring in these alarming trends, the CDC is actively working to reverse this epidemic by helping to identify people with prediabetes, prevent type 2 diabetes and associated complications, and improve overall health. It has launched the National Diabetes Prevention Program (NDPP), aiming to reduce the incidence by nearly 60%. Since January 2016, CDC, ADA and the American Medical Association (AMA) have partnered with the Ad Council to initiate public service advertising (PSA) campaigns about prediabetes.

Such initiatives are expected to significantly bolster prospects for smart insulin pens sales across the country. Numerous manufacturers have made inroads within the United States market. For instance, Novo Nordisk’s NovoPen® 6 and NovoPen Echo® Plus were approved for usage in 2019, capable of recording and storing the last 800 doses of injections, including airshot, facilitating effective insulin management.

Piercing the Future: Exploring the Surge in Needle-Free Injections and its Impact on Sales in the United Kingdom

Healthcare providers across the United Kingdom are highly emphasizing on the need to include needle-free insulin injections, amid the increasing tilt towards non-invasive surgeries. Needle-free injection helps eliminate the pain and trauma associated with needle insertion. Hence, smart insulin pens incorporating numerous modern techniques are acquiring significant ground.

A notable development includes the InsuJetTM System, manufactured and marketed through Spirit Healthcare Ltd. Available upon prescription; the system deploys a special, needle-free nozzle which releases a fine jet stream of insulin, easily penetrating the skin. Subsequently, the insulin follows the path of least resistance, spreading evenly in the subcutaneous layer. It acts more swiftly as well and is reusable.

The InjexTM technology deploys a similar jet streaming mechanism which reduces patient trauma by doing away with the need to externally penetrate human skin with insulin needles. Currently, these technologies are in their nascent stages, and are expected to assume concrete shape soon enough. These breakthroughs will usher in a key revolutionary technique in the field of diabetes treatment in the United Kingdom, widening the scope for smart insulin pen sales across the long-run forecast period.

Germany's Insulin Innovation: A Magnet for High Investments in Smart Insulin Pens

Germany is poised to emerge as a highly lucrative hub for smart insulin pens, given the extensive investment volumes to address the ever growing burden of diabetes mellitus across the German population. The prevalence of known Type 2 diabetes in the German adult population in 2010 was 7-8%. Patients with diabetes have around 1.8 times higher expenses compared to people without the disease.

Numerous technological advancements have been relied upon to reduce this burden on patients and practitioners alike. For instance, Emperra GmbH offers the ESYSTA smart insulin pen which automatically transfers the amounts of insulin dispensed via the ISM wireless technology to ESYSTA Basis. It is capable of holding as much as 60 units of insulin; stores 1,000 data sets; and sends data to a cloud based system for easy storage.

Pendiq Intelligent Diabetes Care has created the Pendiq 2.0 digital insulin pens. To date, these devices are only available in Germany, and are compatible with U-100 (3 ml) lispro and aspart rapid-acting insulin cartridges. They are capable of storing the last 1,000 entries of injection dates, times and quantities, which users can view on an OLED display. Its Bluetooth compatibility allows data transmission to a smartphone app called dialife, available for both Android and Apple smartphones.

From the Eiffel Tower to Innovative Insulin Care: France Paves the Way for Smart Insulin Pens Revolution

The French smart insulin pens market is expected to witness notable developments in the future, with the most recent development being the collaboration between BioCorp and Roche Diabetes Care France. Together, both companies launched the Mallya smart insulin pen device in April 2021. Developed by BioCorp, Mallya is an intelligent sensor for insulin injection pens with a CE mark certification.

The French device maker’s smart sensor connects to most disposable insulin injection pens to collect data about each injection. Mallya automatically transmits the data to Roche’s Gluci-Chek smartphone app over Bluetooth. The dosage, insulin type, date and time information can then be logged and shared with healthcare providers via the Roche Diabetes Care platform.

The companies announced the collaboration way back in 2020. This collaboration marks yet another milestone in the history of French diabetes treatment. An estimated 6% of the French population is afflicted by diabetes. Fortunately, patients are able to avail good quality treatment amid 100% coverage by the statutory health insurance. With further investments in store to improve diabetic care, the smart insulin pens market will further expand in the future.

Unleashing the Sweet Revolution: Exploring the Golden Opportunities in India's Smart Insulin Pens Market

India has an estimated 77 million people with diabetes, making it the second most affected country in the world. As of 2019, one in six people (17%) in the world with diabetes is from India. According to the International Diabetes Federation, this number is projected to reach 134 million by 2045. Naturally, the scope for enhanced quality treatment is broadening with each passing year.

As per the 2019 National Diabetes and Diabetic Retinopathy Survey report released by the Ministry of Health and Family Welfare, the prevalence was found to be nearly 12% in people over the age of 50. Majority of the cases are of type-2 diabetes. In order to reduce this incidence, the Government of India initiated the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) in 2010.

Consequently, the scope for diabetes treatment has acquired immense importance, thereby facilitating the entry of key smart insulin pens manufacturers. Some of the insulin pens available include the Hyaluronic Injection Pen (Monarch Skin Derma), Eglucent Kwickpen (Serum Biotec Limited), Insulin Degludec Tresiba Flex Touch (Kay Biotech Pvt. Ltd.) and Humalog Kwikpen- Insulin Lispro (R-DNA Origin) (Eli Lily) among others.

The Great Dragon's Opportunity: Exploring the Alluring Landscape of the Chinese Smart Insulin Pens Market

China represents a highly attractive investment destination for key smart insulin pens manufacturers. Bulk of the Chinese market’s growth is determined by the presence of a plethora of regional level manufacturers. This heightened presence is largely attributable to the fact that China has the world’s largest number of diabetics. China is home to over a quarter of the world’s diabetic patients.

The International Diabetes Federation, there are around 425 million adults living with diabetes- with 114 million cases in China alone. More than half of these cases remain undiagnosed. Furthermore, the World Health Organization advocates that there are nearly three times more diabetics today than over three decades back, with the surge being significant across China. Hence, governmental efforts to curb this epidemic have been increasing in the recent years, paving way for high smart insulin pens uptake.

Some prominent regional level manufacturers include HK Zion Industry Co. Ltd. (Guangzhou, Guangdong), Melson Medical Corporation Ltd. (Shanghai), Guangzhou Linuo Beauty Electronic Technology Co. Ltd. (Guangzhou), Jiangsu Jichun Medical Devices Co. Ltd. (Jiangsu) and Shanghai Intrag Medical Techs Co. Ltd. (Shanghai) among others.

Category-wise Insights

Cutting the Cord: The Rise of Bluetooth Connected Smart Insulin Pens in Diabetes Management

By connectivity, Bluetooth connected smart insulin pens are expected to register a staggering growth rate, expected to surpass the billion dollar mark in the short run. These “smart” insulin pens are poised to offer not only a more user-friendly insulin delivery option, but also track dosing data that can be shared on digital platforms and integrated with other vital information.

The device exhibits tremendous potential, as until now, only one product has been approved by the US Food & Drug Administration- that of Companion Medical’s Bluetooth-enabled InPen. It is a reusable pen that works with short-acting insulin cartridges (Humalog, Novolog and Fiasp) which can be dosed in half units. Numerous companies, such as Bigfoot Unity and Eli Lily are currently working to launch their own versions of smart insulin pens, widening growth prospects.

Rising Tides: The Surging Demand for Type-2 Diabetes Treatment as Hope Ignites

By indication, type-2 diabetes treatment is likely to generate significant revenue streams in the future, attributed to its high incidence amongst all population age groups. Smart insulin pens have played an important role in transforming diabetic care, ushering in a connected care ecosystem for patients, providers and health systems respectively.

Existing pens are enhanced with real-time wireless connectivity, digital dose capture, and integration with personalized dosing decision support. Automatic dose capture can promote effective retrospective review of insulin dose data, particularly when paired with glucose data. In November 2020, Medtronic Plc launched CGM-integrated smart insulin pen for multiple daily injections.

The Insulin Express: Navigating the Smart Insulin Pens Distribution Maze

Retail pharmacies emerged as the primary source of smart insulin pens sales until the recent past, reaching almost half-a-billion dollars as of 2019. The easy availability of the pens and close proximity to residences rendered it the primary distribution channel. Post diagnosis and treatment, hospital patients often frequent retail pharmacies to avail their medications.

Since the outbreak of the pandemic crisis, e-commerce sales of smart insulin pen have registered a significant uptick. With mandatory social distancing measures prompting patients to remain indoors, hospital visits for diabetes treatment have declined, prompting enhanced adoption of home-grade treatment. Most online pharmacies have been experiencing a major incline in online sales of smart insulin pens.

Pioneers and Innovators: Leading the Charge in Smart Insulin Pens Market

The competitive landscape of the smart insulin pens market is heating up as key players strive to capture a larger market share. Companies such as Digital Medics, Emperra GmbH e-Health Technologies, and others are continuously innovating to offer advanced features like Bluetooth connectivity, personalized dose recommendations, and real-time data tracking.

New entrants are bringing disruptive technologies such as AI algorithms and cloud-based platforms into the market. The focus is not only on improving insulin delivery but also on enhancing the overall user experience with user-friendly designs and intuitive interfaces. As competition intensifies, the smart insulin pens market is witnessing a flurry of exciting developments that are revolutionizing diabetes management and offering individuals with diabetes a range of options to choose from.

Key Players in the Market

  • Digital Medics Pty Ltd.
  • Emperra GmbH e-Health Technologies
  • Companion Medical Inc.
  • Sanofi Aventis LLC
  • Novo Nordisk A/S
  • Eli Lily and Company
  • Companion Medical
  • Diabnext
  • Jiangsu Delfu Medical Device Co. Ltd.
  • DIAMESCO Co Ltd.
  • Patients Pending Ltd (Bigfoot Biomedical Inc.)
  • BERLIN-CHEMIE

How can Smart Insulin Pens Manufacturers expand in the Market?

Strategies for Smart Insulin Pens Manufacturers to Expand in the Market

  • Invest in R&D for innovative smart insulin pens with advanced features.
  • Collaborate with pharma, providers, and tech for expertise and resources.
  • Target segments with tailored solutions for diverse diabetic demographics.
  • Develop inclusive marketing campaigns highlighting smart insulin pen benefits for stakeholders.
  • Regulatory compliance, expand in emerging markets, adapt to local needs.

Product Portfolio:

  • Sanofi Aventis LLC offers a diverse product portfolio in the pharmaceutical industry, including a range of medications and treatments for various therapeutic areas such as diabetes, cardiovascular diseases, immunology, and rare diseases.
  • Novo Nordisk A/S specializes in the production of pharmaceutical products and devices for diabetes care, including insulin analogs, insulin delivery systems, and digital solutions. Their portfolio encompasses a comprehensive range of products for diabetes management, catering to the needs of patients worldwide.

Report Scope

Attribute Details
Market Value in 2023 US$ 3,927.3 million
Market Value in 2033 US$ 8,750.7 million
Growth Rate CAGR of 8.3% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2017 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Indication
  • Connectivity
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Digital Medics Pty Ltd.
  • Emperra GmbH e-Health Technologies
  • Companion Medical Inc.
  • Sanofi Aventis LLC
  • Novo Nordisk A/S
  • Eli Lily and Company
  • Companion Medical
  • Diabnext
  • Jiangsu Delfu Medical Device Co. Ltd.
  • DIAMESCO Co Ltd.
  • Patients Pending Ltd (Bigfoot Biomedical Inc.)
  • BERLIN-CHEMIE
Customization & Pricing Available Upon Request

Key Segments Covered in the Smart Insulin Pens Industry Survey

By Indication:

  • Diabetes Type I
  • Diabetes Type II

By Connectivity:

  • Bluetooth Connected
  • USB Connected

By Distribution Channel:

  • Clinics & Ambulatory Surgical Centers
  • E-Commerce
  • Retail Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

What is the Smart Insulin Pens Market's growth CAGR?

Through 2033, the market is projected to develop at a CAGR of 8.3%.

What will the market be worth in 2023?

In 2023, the market is expected to attain US$ 3,927.3 million.

What size will the Smart Insulin Pens Market be in 2033?

The market is projected to rise to US$ 8,750.7 million by 2033.

Which Connectivity segment to lead the market?

Bluetooth-connected smart insulin pens are projected to boom at an astonishing pace in terms of connectivity.

Which indication category may take control of the market?

Based on indications, type 2 diabetes treatment is going to produce large revenue streams.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Indication, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Indication, 2023 to 2033

        5.3.1. Diabetes Type I

        5.3.2. Diabetes Type II

    5.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Connectivity

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Connectivity, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Connectivity, 2023 to 2033

        6.3.1. Bluetooth Connected

        6.3.2. USB Connected

    6.4. Y-o-Y Growth Trend Analysis By Connectivity, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Connectivity, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Clinics & Ambulatory Surgical Centers

        7.3.2. E-Commerce

        7.3.3. Retail Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The USA

            9.2.1.2. Canada

        9.2.2. By Indication

        9.2.3. By Connectivity

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Indication

        9.3.3. By Connectivity

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Indication

        10.2.3. By Connectivity

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Indication

        10.3.3. By Connectivity

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Indication

        11.2.3. By Connectivity

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Indication

        11.3.3. By Connectivity

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Indication

        12.2.3. By Connectivity

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Indication

        12.3.3. By Connectivity

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Indication

        13.2.3. By Connectivity

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Indication

        13.3.3. By Connectivity

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Indication

            14.1.2.2. By Connectivity

            14.1.2.3. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Indication

            14.2.2.2. By Connectivity

            14.2.2.3. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Indication

            14.3.2.2. By Connectivity

            14.3.2.3. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Indication

            14.4.2.2. By Connectivity

            14.4.2.3. By Distribution Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Indication

            14.5.2.2. By Connectivity

            14.5.2.3. By Distribution Channel

    14.6. United Kingdom

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Indication

            14.6.2.2. By Connectivity

            14.6.2.3. By Distribution Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Indication

            14.7.2.2. By Connectivity

            14.7.2.3. By Distribution Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Indication

            14.8.2.2. By Connectivity

            14.8.2.3. By Distribution Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Indication

            14.9.2.2. By Connectivity

            14.9.2.3. By Distribution Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Indication

            14.10.2.2. By Connectivity

            14.10.2.3. By Distribution Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Indication

            14.11.2.2. By Connectivity

            14.11.2.3. By Distribution Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Indication

            14.12.2.2. By Connectivity

            14.12.2.3. By Distribution Channel

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Indication

            14.13.2.2. By Connectivity

            14.13.2.3. By Distribution Channel

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Indication

            14.14.2.2. By Connectivity

            14.14.2.3. By Distribution Channel

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Indication

            14.15.2.2. By Connectivity

            14.15.2.3. By Distribution Channel

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Indication

            14.16.2.2. By Connectivity

            14.16.2.3. By Distribution Channel

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Indication

            14.17.2.2. By Connectivity

            14.17.2.3. By Distribution Channel

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Indication

            14.18.2.2. By Connectivity

            14.18.2.3. By Distribution Channel

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Indication

            14.19.2.2. By Connectivity

            14.19.2.3. By Distribution Channel

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Indication

            14.20.2.2. By Connectivity

            14.20.2.3. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Indication

        15.3.3. By Connectivity

        15.3.4. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Digital Medics Pty Ltd.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

                16.1.1.5.2. Product Strategy

                16.1.1.5.3. Channel Strategy

        16.1.2. Emperra GmbH e-Health Technologies

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

                16.1.2.5.2. Product Strategy

                16.1.2.5.3. Channel Strategy

        16.1.3. Companion Medical Inc.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

                16.1.3.5.2. Product Strategy

                16.1.3.5.3. Channel Strategy

        16.1.4. Sanofi Aventis LLC

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

                16.1.4.5.2. Product Strategy

                16.1.4.5.3. Channel Strategy

        16.1.5. Novo Nordisk A/S

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

                16.1.5.5.2. Product Strategy

                16.1.5.5.3. Channel Strategy

        16.1.6. Eli Lily and Company

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

                16.1.6.5.2. Product Strategy

                16.1.6.5.3. Channel Strategy

        16.1.7. Companion Medical

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

                16.1.7.5.2. Product Strategy

                16.1.7.5.3. Channel Strategy

        16.1.8. Diabnext

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

                16.1.8.5.2. Product Strategy

                16.1.8.5.3. Channel Strategy

        16.1.9. Jiangsu Delfu Medical Device Co. Ltd.

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

                16.1.9.5.2. Product Strategy

                16.1.9.5.3. Channel Strategy

        16.1.10. DIAMESCO Co Ltd.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

                16.1.10.5.2. Product Strategy

                16.1.10.5.3. Channel Strategy

        16.1.11. Patients Pending Ltd (Bigfoot Biomedical Inc.)

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

                16.1.11.5.2. Product Strategy

                16.1.11.5.3. Channel Strategy

        16.1.12. BERLIN-CHEMIE

            16.1.12.1. Overview

            16.1.12.2. Product Portfolio

            16.1.12.3. Profitability by Market Segments

            16.1.12.4. Sales Footprint

            16.1.12.5. Strategy Overview

                16.1.12.5.1. Marketing Strategy

                16.1.12.5.2. Product Strategy

                16.1.12.5.3. Channel Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Insulin Delivery Pen Market

Published : May 2024

Healthcare

Insulin Management System Market

Published : January 2023

Healthcare

Insulin Pens Market

Published : December 2022

Explore Healthcare Insights

View Reports

Smart Insulin Pens Market